Source: http://www.google.com/patents/US4634447?dq=5,646,839
Timestamp: 2017-05-24 05:43:21
Document Index: 797261770

Matched Legal Cases: ['art  6200', 'art  5700', 'art  8100', 'art  6700', 'art  8900', 'art  8100']

Patent US4634447 - Method for manufacturing artificial organ - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA method for the manufacture of an artificial organ having a film of a fat-soluble vitamin deposited on the surfaces of parts of said artificial organ susceptible to contact with body fluid in motion through a zone for flow of said body fluid within said artificial organ, which method is characterized...http://www.google.com/patents/US4634447?utm_source=gb-gplus-sharePatent US4634447 - Method for manufacturing artificial organAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS4634447 APublication typeGrantApplication numberUS 06/818,878Publication dateJan 6, 1987Filing dateJan 14, 1986Priority dateSep 9, 1982Fee statusPaidAlso published asDE3378461D1, EP0103816A2, EP0103816A3, EP0103816B1, US4588407, US4643715Publication number06818878, 818878, US 4634447 A, US 4634447A, US-A-4634447, US4634447 A, US4634447AInventorsKeinosuke Isono, Keiji NaoiOriginal AssigneeTerumo Kabushiki KaishaExport CitationBiBTeX, EndNote, RefManPatent Citations (2), Referenced by (12), Classifications (21), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetMethod for manufacturing artificial organ
9. A method according to claim 1, wherein said drying is effected by causing a gas inert to said fat-soluble vitamin to be passed at a temperature in the range of from 10° to 80° C. through said zone for flow of said body fluid.
18. A method according to claim 14, wherein said drying is effected by causing a gas inert to said fat-soluble vitamin to be passed at a temperature in the range of from 10° to 80° C. through said zone for flow of said body fluid.
This invention is directed to a method for the manufacture of an artificial organ wherein the organic solvent is at least one member selected from the group consisting of a chlorofluorohydrocarbon, a fluorohydrocarbon and a lower alcohol. This invention is directed to a nethod for the manufacture of an artificial organ wherein the concentration of the fat-soluble vitamin in the solution thereof in the organic solvent is in the range of from 0.01 to 10 w/v %. This invention is further directed to a method for the manufacture of an artificial organ wherein the drying of the deposited solution is effected by passing through the aforementioned body fluid-flowing zone a gas inert to the aforementioned fat-soluble vitamin at a temperature in the range of from 10° to 80° C. This invention is also directed to a method for the manufacture of a sterilized artificial organ wherein the aforementioned physiologically harmless liquid comprises water, physiological saline solution, or an aqueous glycerin solution.
The fat-soluble vitamin is dissolved at a concentration in the range of from 0.01 to 10 w/v %, preferably from 0.05 to 2.0 w/v %, in an organic solvent. The solution thus prepared is caused to flow into the body fluid-flowing zone of the artificial organ (the blood-flowing zone in the case of the artificial kidney illustrated in FIG. 1 and FIG. 2) and allowed to remain in contact with the zone for a stated period such as, for example, 30 seconds to 60 minutes, preferably 1 to 10 minutes so as to have the inner surfaces of the parts in the aforementioned zone such as, for example, the inner surfaces of the tube 14, the cavity defined by the header 10 and the potting ring 6, the hollow fiber, the cavity defined by the header 11 and the potting ring 7, and the tube 15 apply wetted with the aforementioned fat-soluble vitamin. A film of the aforementioned fat-soluble vitamin is deposited on the aforementioned surfaces by subsequently discharging the solution from the artificial organ and introducing into the artificial organ a gas inert to the fat-soluble vitamin such as, for example, air, nitrogen or carbon dioxide gas at a temperature in the range of from 10° to 80° C., preferably from 15° to 30° C. thereby expelling the organic solvent by distillation from the solution. When necessary, the artificial organ may be rinsed with water. In this case, the film of the fat-soluble vitamin may be formed particularly in the portion packed with the permeating membranes. Especially in the artificial organ incorporating regenerated cellulose membranes which are liable to induce hemodialysis leukopenia, a notable effect in curbing this detestable phenomenon can be obtained by having the film of fat-soluble vitamin deposited preponderantly on the portion packed with the permeating membranes. Where such permeating membranes are made of regenerated cellulose, particularly regenerated cellulose of the cuprammonium process, the aforementioned solution of fat-soluble vitamin in the organic solvent may additionally incorporate glycerin therein. The addition of glycerin serves the purpose of enhancing the hydrophilicity of the permeating membrane. It is, therefore, effective in artificial organs such as artificial kidney and artificial liver which are required to use hydrophilic permeating membranes. The concentration of glycerin in the aforementioned solution is in the range of from 0.1 to 10 w/v %, preferably from 1 to 5 w/v %.
TABLE 3______________________________________(Vitamin E 1.0%)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  6200    100.0   61.3    100.0  43.3 100.0 5 min.  5710    92.1    57.3    93.5   39.4 91.010     5530    89.2    56.3    91.8   39.9 92.115     5520    89.0    54.8    89.4   39.2 90.520     5200    83.9    53.4    97.1   39.1 90.330     5240    84.5    50.6    82.5   39.7 91.745     5150    83.1    46.7    76.1   39.5 91.2 1 hr. 6030    97.3    46.1    75.2   38.8 89.6 2     7380    119.0   42.4    69.2   39.3 90.7 3     6650    107.3   34.9    56.9   41.0 94.7 4     6710    108.2   37.1    60.5   41.3 95.4 5     7640    123.2   37.9    61.8   40.8 94.2 6     7490    120.8   36.8    60.0   39.9 92.1______________________________________ PIC means percent of initial ccount.
TABLE 4______________________________________(Vitamin 0.1%)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  5700    100.0   61.6    100.0  45.4 100.0 5 min.  5340    93.7    53.2    86.4   40.8 89.910     5410    94.9    54.4    88.3   40.3 88.815     5030    88.2    53.9    87.5   40.6 89.420     4780    78.6    47.1    76.5   40.6 89.430     4630    81.2    42.4    68.8   42.2 93.045     5080    89.1    38.8    63.0   40.2 88.5 1 hr. 5040    88.4    37.9    61.5   40.5 89.2 2     6320    110.9   32.2    52.3   39.5 87.0 3     7640    134.0   33.8    54.9   39.8 87.7 4     9750    171.1   34.3    55.7   39.1 86.1 5     10590   185.5   32.8    52.4   40.3 88.8 6     11870   208.2   29.9    48.5   39.0 85.9______________________________________
TABLE 5______________________________________(Vitamin E none)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  8100    100.0   86.4    100.0  44.4 100.0 5 min.  4230    52.2    79.8    92.4   39.9 89.910     3850    47.5    76.8    88.9   39.2 88.315     4100    50.6    73.2    84.7   41.2 92.820     4520    55.8    71.4    82.6   40.3 90.830     6820    84.2    69.8    80.8   38.4 86.545     6870    84.8    66.7    77.2   39.4 88.7 1 hr. 8790    108.5   64.8    75.0   38.9 87.6 2     11520   142.2   54.7    63.3   39.7 89.4 3     13720   169.4   47.8    55.3   38.2 86.5 4     18130   223.8   50.3    58.2   38.7 87.2 5     22500   277.8   52.3    60.5   37.1 83.6 6     22690   280.1   55.7    64.5   36.6 82.4______________________________________
TABLE 6______________________________________(Vitamin E 1.0%)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  6700    100.0   71.0    100.0  48.0 100.0 5 min.  5830    87.0    68.0    95.8   42.8 89.210     5050    75.4    66.0    93.6   41.8 87.115     4940    73.7    68.5    96.5   44.7 93.120     4950    73.9    63.5    89.4   44.6 92.930     5930    88.5    59.5    83.8   41.3 86.045     6590    98.4    55.1    77.6   43.7 91.0 1 hr. 7650    114.2   58.2    82.0   43.9 91.5 2     9380    140.0   51.8    73.0   43.0 89.6 3     10400   155.2   43.8    61.7   43.4 90.4 4     9950    148.5   36.8    51.8   44.4 92.5 5     10740   160.3   38.5    54.2   43.8 91.3 6     11690   174.5   39.3    55.4   42.7 89.0______________________________________ PIC means percent of initial ccount.
TABLE 7______________________________________(Vitamin E 0.1%)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  8900    100.0   85.7    100.0  51.7 100.0 5 min.  8210    92.2    93.0    108.5  42.8 82.710     6700    75.2    85.3    99.5   46.3 89.615     6110    68.7    79.7    93.0   47.4 91.720     6080    68.3    74.8    87.3   46.8 90.530     6780    76.2    63.3    73.9   47.3 91.545     7660    85.4    57.8    67.4   48.3 93.4 1 hr. 8180    91.9    53.9    62.9   47.4 91.6 2     7850    88.2    46.5    54.3   48.1 93.0 3     10890   122.4   38.9    45.4   45.3 87.2 4     13120   147.4   32.5    37.9   45.3 87.6 5     13720   154.2   36.6    42.7   45.6 88.2 6     13700   153.9   39.2    45.7   43.4 83.9______________________________________
TABLE 8______________________________________(Vitamin E none)W B C          P L T          H C T          PIC             PIC         PICTime   /mm3          (%)     × 104 /mm3                          (%)    %    (%)______________________________________Start  8100    100.0   86.4    100.0  44.4 100.0 5 min.  4230    52.2    79.8    92.4   39.9 89.910     3850    47.5    76.8    88.9   39.2 88.315     4100    50.6    73.2    84.7   41.2 92.820     4520    55.8    71.4    82.6   40.3 90.830     6820    84.2    69.8    80.8   38.4 86.545     6870    84.8    66.7    77.2   39.4 88.7 1 hr. 8790    108.5   64.8    75.0   38.9 87.6 2     11520   142.2   54.7    63.3   39.7 89.4 3     13720   169.4   47.8    55.3   38.2 86.5 4     18130   223.8   50.3    58.2   38.7 87.2 5     22500   277.8   52.3    60.5   37.1 83.6 6     22690   280.1   55.7    64.5   36.6 82.4______________________________________
TABLE 9______________________________________(Vitamin E 0.5%)W B C         P L T          H C TTime /mm3        PIC (%)  × 104 /mm3                         PIC (%)                                %    PIC (%)______________________________________ 0   7870    100.0    84.4    100.0  46.7 100.0 5   8030    102.0    84.8    100.5  41.0 87.810   7290     92.6    85.0    100.7  44.7 95.715   6550     83.2    81.2    96.2   42.4 90.820   6300     80.1    77.0    91.2   42.3 90.630   7290     92.6    72.0    85.3   42.7 91.445   8000    101.1    67.1    79.5   41.1 88.060   8930    113.5    62.8    74.4   41.4 88.7120  11800   149.9    62.1    73.6   39.5 84.6______________________________________
TABLE 10______________________________________(Vitamin E none)Time W B C        P L T          H C T(min)/mm3        PIC (%)  × 104 /mm3                         PIC (%)                                %    PIC (%)______________________________________ 0   8880    100.0    66.7    100.0  47.0 100.0 5   7160    80.6     65.1    97.6   39.5 84.010   5900    66.4     63.5    95.2   40.6 86.415   4480    50.5     60.7    91.0   40.8 86.820   5030    56.6     58.5    87.7   40.5 86.230   6530    73.5     52.9    79.3   40.4 86.045   7790    87.7     53.1    79.6   40.4 86.060   8340    93.9     49.7    74.5   40.0 85.1120  9610    108.2    45.4    68.1   38.6 82.1______________________________________
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4211602 *May 4, 1978Jul 8, 1980Brumfield Robert CSurface treatment for blood dialysis cartridgesUS4354933 *Feb 23, 1981Oct 19, 1982Lester James PImplantable artificial kidney* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS4842472 *Nov 30, 1987Jun 27, 1989Pcm (Long Buckby) Engineering Ltd.Vehicle recovery unitUS5092886 *Sep 29, 1988Mar 3, 1992Dobos Hardy MatyasImplantable artificial kidneyUS5116307 *Jul 9, 1990May 26, 1992Collins Harvey TMethod and system for treatment of AIDSUS5192308 *Apr 19, 1991Mar 9, 1993E. I. Du Pont De Nemours And CompanyVascular prosthesis with an elastomer coatingUS5605835 *Jan 20, 1995Feb 25, 1997Regents Of The University Of MinnesotaBioreactor device with application as a bioartificial liverUS5780100 *May 18, 1995Jul 14, 1998Powderject Vaccines, Inc.Method and apparatus for preparing sample cartridges for particle acceleration deviceUS5827904 *Sep 27, 1996Oct 27, 1998Hahn; DavidMedical implant compositionUS5981211 *Oct 7, 1996Nov 9, 1999Regents Of The University Of MinnesotaMaintaining cells for an extended time by entrapment in a contracted matrixUS6001288 *Dec 24, 1997Dec 14, 1999Terumo Kabushiki KaishaProcess for producing a hollow fiber membrane having a hydrophobic coatingUS7083653 *Aug 12, 2004Aug 1, 2006Charles Edward JenningsImplantable human kidney replacement unitUS20060036332 *Aug 12, 2004Feb 16, 2006Jennings Charles EImplantable human kidney replacement unitDE19515137A1 *Apr 25, 1995Oct 31, 1996Thueringisches Inst TextilVerfahren zur Herstellung von Cellulose-Flachfolien* Cited by examinerClassifications U.S. Classification623/23.65, 427/2.3, 106/287.35, 210/646, 427/372.2, 422/44, 427/235, 427/417, 210/645, 427/2.24International ClassificationB01D65/02, B01D67/00, B01D63/02, A61M1/18Cooperative ClassificationB01D2321/32, B01D67/0088, B01D63/021, B01D65/022European ClassificationB01D65/02B, B01D63/02B, B01D67/00R14Legal EventsDateCodeEventDescriptionJun 25, 1990FPAYFee paymentYear of fee payment: 4Jun 20, 1994FPAYFee paymentYear of fee payment: 8Jun 22, 1998FPAYFee paymentYear of fee payment: 12Aug 28, 2002ASAssignmentOwner name: ASAHI MEDICAL CO., LTD., JAPANFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TERUMO KABUSHIKI KAISHA (AKA TERUMO CORPORATION);REEL/FRAME:013231/0052Effective date: 20020725RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services